
													
															
															Year
															DEALS // DEV.
															Country
															
															Therapeutic Area
															Study Phase
															Deal Type
															Product Type
															Dosage Form
															Lead Product
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Brabant Development Agency
Deal Size : Undisclosed
Deal Type : Financing
Cantoni Secures Financing to Advance Novel Non-Incretin Obesity Drug into IND Phase
Details : The financing will be used to advance company's lead asset, a small molecule inhibitor of NNMT, into IND enabling phase for obesity and its comorbidities.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 16, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Brabant Development Agency
Deal Size : Undisclosed
Deal Type : Financing
